Etid klinik pou Limfom nan Tennessee
15 etid pou Limfom ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Sarah Cannon Research Institute Oncology Partners, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07015242A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- St. Jude Children's Research Hospital, Memphis
Ap rekriteFaz 1/2
Jiska laj 25 · Tout sèks · Mizajou Sep 25, 2026 · NCT04094610A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07221500CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Saint Jude Children's Research Hospital, Memphis
Ap rekriteFaz 1/2
12 Months – 21 Years · Tout sèks · Mizajou Sep 11, 2026 · NCT04870944TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07082803Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07284433Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Vanderbilt University Medical Center, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
Ap rekriteFaz 1/2
Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Tennessee Oncology, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT04830137CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
- St. Jude Children's Research Hospital, Memphis
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou Jan 23, 2026 · NCT06326463cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881HPC Offered for PRESERVE Expansion
- Tristar Centennial Medical Center, Nashville
Ap rekriteEtid obsèvasyon
Laj 12 a 80 · Tout sèks · Mizajou Aug 28, 2025 · NCT07145411Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.